Photodynamic therapy comprising two light exposures at different wavelengths
The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps: (a) topical application or subcutaneous injection of said composition to an area of the skin of said patient, (b) exposure of at least said area of the skin to light with a wavelength spectrum similar or identical to sun light for a duration of 30 min to 5 hours, and (c) exposure of at least said area of the skin to light of a wavelength spectrum comprising only one maximum in the absorbance spectrum of said photosensitizer as well as to methods of treating dermatological disease using the outlined steps and kits of parts comprising such compositions and light sources suitable to apply the respectively indicated light.
1 . A method of preventing or treating a dermatological disease in a patient, the method comprises the following order of steps:
(a) topical application or subcutaneous injection of a composition comprising a photosensitizer to an area of the skin of said patient,
(b) exposure of at least said area of the skin to light having a wavelength spectrum of 360 nm to 460 nm for a duration of 30 min to 5 hours, and
(c) exposure of at least said area of the skin to light having a wavelength spectrum of 570 nm to 670 nm.
2 . The method of claim 1 , wherein the composition is formulated as a nanoemulsion comprising:
(a) at least one aqueous component, and
(b) a carrier, which comprises:
(i) at least one lipophilic component,
(ii) at least one surfactant, and
(iii) at least one alcohol.
3 . The method of claim 2 , wherein
the carrier is present in the aqueous component, and/or
the surfactant is present in an amount of from 1% by weight to 30% by weight and the alcohol is present in an amount of from 0.1% by weight to 10% by weight, based on the total weight of the nanoemulsion.
4 . The method of claim 2 , wherein the aqueous component is present in an amount of from 50% by weight to 98% by weight, based on the total weight of the nanoemulsion.
5 . The method of claim 2 , wherein:
the at least one alcohol is isopropylalcohol and/or 1-propylalcohol, and/or
the at least one lipophilic component are triglycerides and/or a mixture thereof, and/or
the at least one surfactant is lecithin and/or a polyoxyethylene-type surfactant, and/or
the mean diameter of particles of the nanoemulsion ranges from 10 to 100 nm.
6 . The method of claim 2 , wherein the photosensitizer is selected from 5-aminolevulinic acid (ALA), ALA-esters, in particular methyl-5-amino-4-oxopentanoat, or hexyl-5-amino-4-oxopentanoat or their derivatives.
7 . The method of claim 1 , wherein the light used in step (c) has a wavelength spectrum of 570 nm to about 635 nm.
8 . The method of claim 1 , wherein the area of the skin comprises skin affected by the disease or skin prone to be affected by the disease.
9 . The method of claim 1 , wherein there is a residence time interval subsequent to step (a) and prior to step (b) of 1 to 90 min, in particular of 15 to 30 min, preferably in the absence of light exposure.
10 . The method of claim 1 , wherein the light used in step (b) has a wavelength spectrum of 360 nm to 440 nm.
11 . The method of claim 1 , wherein the light of step (b) has a wavelength spectrum of 380 nm to 460 nm.
12 . The method of claim 11 , wherein the light of step (b) has equal irradiance throughout the wavelength spectrum.
13 . The method of claim 11 , wherein the light of step (b) has an irradiance peak at around 405 nm.
14 . The method of claim 1 , wherein the exposure of step (b) has a duration of 30 min to 1 hour.
15 . The method of claim 1 , wherein the exposure of step (c) has a duration of at least 5 minutes, preferably of 5-60 minutes.
16 . The method of claim 1 , wherein the dermatological disease is a hyperproliferative disease, preferably keratosis, more preferably actinic keratosis; basal carcinoma, squamous cell carcinoma in situ, warts, acne, rosacea or an inflammatory or infectious dermatological condition.
17 . A method of treating or preventing a dermatological disease in a patient in need thereof comprising:
(a) topical application or subcutaneous injection of a composition comprising a photosensitizer to an area of the skin of said patient,
(b) exposure of at least said area of the skin to light with a wavelength spectrum of 360 nm to 460 nm for a duration of 30 min to 5 hours, preferably 1 to 3 hours, more preferably 1 to 2 hours, and
(c) exposure of at least said area of the skin to light with a wavelength spectrum of 570 nm to 670 nm.
18 . The method of claim 17 , wherein the composition is formulated as a nanoemulsion comprising:
(a) at least one aqueous component, and
(b) a carrier, which comprises:
(i) at least one lipophilic component,
(ii) at least one surfactant, and
(iii) at least one alcohol.
19 . A kit comprising a light source capable of emitting light with a wavelength spectrum and preferably also irradiance similar or identical to sun light and violet-blue light and an instruction manual for carrying out steps (b) and (c) of the method of claim 17 .
20 . A light source capable of emitting light with a wavelength spectrum and preferably also irradiance similar or identical to sun light and violet-blue light and a controller, wherein the controller is programmed for carrying out steps (b) and (c) of the method of claim 17 .